Back to Results
First PageMeta Content
National Psoriasis Foundation / Psoriatic arthritis / Secukinumab / Biologic / Generalized pustular psoriasis / Light therapy / Mark G. Lebwohl / Psoriasis / Medicine / Health


Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca
Add to Reading List

Document Date: 2015-05-13 10:22:20

Open Document

File Size: 258,13 KB

Share Result on Facebook

City

Montréal / Halifax / Basel / /

Company

Fleischer AB / Nestle / Novartis Group / Novartis Pharmaceuticals Canada Inc. / Gottlieb AB / Novartis Pharmaceuticals Inc. / /

Country

Switzerland / Canada / /

Currency

USD / /

/

Event

FDA Phase / /

Facility

Dalhousie University / /

IndustryTerm

generic pharmaceuticals / healthcare field / healthcare solutions / over-the-counter products / /

MedicalCondition

chronic plaque psoriasis / inflammatory arthritis / severe psoriasis / active psoriasis / Barker J. Psoriasis / plaque psoriasis / severe plaque psoriasis / psoriasis / such a psoriatic arthritis / chronic autoimmune disease / medical disease / disease / moderate tosevere plaque psoriasis / inflammatory gene circuits / itching / approved psoriasis / moderate-to-severe plaque psoriasis / Tak Piech C. Disease / inflammation / chronic illnesses23 / human disease / /

MedicalTreatment

Biological therapies / /

Organization

Canadian Skin Patient Alliance / Canadian Association of Psoriasis Patients / National Psoriasis Foundation / Dalhousie University / Secukinumab Administration / /

Person

Brit J Dermatol / Christine Janus / Richard Langley / Tim Maloney / Gregory V / Arch Derm / Elizabeth Tanguay / /

/

Position

Executive Director / President / Manager / messenger / Vice President Argyle Communications / leader / Professor / Director of Dermatology Research / Usher / /

Product

IL-17 / Canada / IL-17A / IL17A1 / /

ProvinceOrState

Quebec / Nova Scotia / /

Technology

alpha / /

URL

http /

SocialTag